PEN

PenumbraD

NYSE / Health Care Equipment & Services

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

28%

Probability

Target price

$370.00

+16.1% vs current

Most likely

Base case

47%

Probability

Target price

$338.00

+6.0% vs current

B-

Bear case

25%

Probability

Target price

$285.00

-10.6% vs current

AI sentiment snapshot

Latest data as of 2026-05-08

AI commentary

Tone is mixed and explicitly tentative. The primary company evidence confirms a solid Q1 print and completed shareholder vote, but this T+3 follow-up still lacks reliable post-print analyst revision, target-change, estimate-change, and market-reaction evidence in the packet or checked sources. By the May 7, 2026 anchor close of $324.65, the stock remained below the $374 per-share transaction reference described in the merger disclosure, implying the market continues to discount regulatory and timing risk more than near-term operating upside. Missing analyst-reaction evidence is a confidence limiter, not positive evidence.

RankAlpha Sentiment Codex - 2026-05-08

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-07-31catalystRegulatory delay could keep the deal spread wide or reprice downsideHigh impact

The checked company filings still show meaningful execution risk rather than a closed deal path. Penumbra's May 7 vote 8-K confirms shareholder approval but not final regulatory completion, and the Q1 10-Q still frames closing as subject to regulatory approvals and other customary conditions [#8-K-2026-05-07; #10-Q-2026-05-06].

2026-08-05catalystQ1 operating results support the standalone franchise, but guidance remains withheldMedium impact

Penumbra's May 6, 2026 earnings 8-K press release reported Q1 2026 revenue of $374.8 million, up 15.6% year over year, with global thrombectomy revenue up 12.1%, embolization and access up 23.8%, gross margin of 67.6%, and net income of $32.6 million [#8-K-2026-05-06]. The company also said it would not provide full-year 2026 guidance or host a conference call because of the pending Boston Scientific acquisition, limiting fresh standalone upside framing despite solid execution [#8-K-2026-05-06].

2026-09-30eventMerger vote passed; remaining driver is regulatory clearance and closing timingHigh impact

Penumbra stockholders approved the merger proposal on May 6, 2026, satisfying the shareholder-vote condition, but consummation still depends on remaining closing conditions including HSR and other regulatory clearances [#8-K-2026-05-07]. Penumbra's Q1 10-Q also says the transaction is expected to be completed in 2026 subject to regulatory approvals and other customary closing conditions [#10-Q-2026-05-06].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-08 • Updated nightlySource: Internal modelMethodology